Skip to main contentAI and Advanced
/
BLUEJET · NSEBSE SENSEX74,314.59-0.03%BSE |
NIFTY 5023,270.6+0.23%NSE |
NIFTY BANK56,055.75-0.42%NSE |
NIFTY IT29,155.6+0.23%NSE |
NIFTY AUTO27,159.15+0.99%NSE |
NIFTY FMCG45,572.7+0.03%NSE |
NIFTY PHARMA26,579.25+1.66%NSE |
NIFTY 50022,654.65+0.54%NSE |
BL
NSE · Equity shares · Biotechnology & Drugs3.15 · 0.56%
Blue Jet Healthcare BLUEJET
NSE:INR 568.2
BSE:INR 565.25
Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.
Headline priceLast market snapshot
Company fundamentalsStale · last-known data
Research sections9 of 9 availableMissing source values remain unavailable, never zero-filled.
AI analysis and Advanced tools for BLUEJET
Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.
Snapshot
Price and key statistics
Reported and computed values remain separate; missing values are not converted to zero.
Previous closeINR 565.05
Day rangeINR 563.25 — INR 576.9
52-week rangeINR 325 — INR 834.95
Volume5.47 L
Market cap11,099.51
P/E38.76
Fundamental highlightsReported values unless marked as computed
Revenue (INR Cr)947.32
Net Income (INR Cr)247.82
Rev Growth (5 Year %)13.68
EPS Growth (5 Year %)12.79
P/E Ratio38.76
EPS14.29
Research path: Interpret Blue Jet Healthcare's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.
Validated OHLC
Interactive price chart
Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.
BLUEJETBlue Jet Healthcare1d · INR · NSE
Loading validated candles…
Auditable calculations
Daily technical summary
Calculated from validated daily candles. Descriptive research only.
Calculating technicals…
Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.
Company reporting
Financial statements
IND AS · INR crore
| Metric | 2026 | 2025 | 2024 |
|---|---|---|---|
| Total Liabilities Shareholders' Equity | 1,641.16 | 1,417.53 | 1,058.85 |
| Cash Equivalents | 60.86 | 32.98 | 40.95 |
| Other Liabilities Total | 5.58 | 4.7 | 4.12 |
| Common Stock Total | 34.69 | 34.69 | 34.69 |
| Other Current Assets Total | 42.43 | 64.04 | 66.85 |
| Total Assets | 1,641.16 | 1,417.53 | 1,058.85 |
| Current Portof LT Debt/Capital Leases | 4.6 | 4.96 | 2.73 |
| Cash | 88.01 | 86.81 | 43.75 |
| Total Equity | 1,359.91 | 1,133.11 | 845.22 |
| Long Term Investments | 45.14 | 5.51 | 19.87 |
| Retained Earnings(Accumulated Deficit) | 1,325.22 | 1,098.42 | 810.53 |
| Total Common Shares Outstanding | 17.35 | 17.35 | 17.35 |
| Tangible Book Valueper Share Common Eq | 78.27 | 65.29 | 48.71 |
| Total Liabilities | 281.25 | 284.42 | 213.62 |
| Total Debt | 42.18 | 21.49 | 3.11 |
| Short Term Investments | 239.31 | 186.69 | 235.49 |
| Cashand Short Term Investments | 388.18 | 306.48 | 320.19 |
| Total Receivables Net | 339.05 | 370.05 | 187.76 |
| Deferred Income Tax | 10.63 | 7.29 | 3.16 |
| Accounts Receivable-Trade Net | 339.05 | 369.52 | 186.85 |
| Property/Plant/Equipment Total-Net | 615.63 | 388.94 | 318.8 |
| Total Current Liabilities | 227.46 | 255.91 | 205.96 |
| Total Inventory | 187.39 | 263.92 | 129.83 |
| Accounts Payable | 56.92 | 89.05 | 30.3 |
| Other Currentliabilities Total | 165.93 | 158.89 | 164.53 |
| Total Long Term Debt | 37.58 | 16.53 | 0.38 |
| Intangibles Net | 2.18 | 0.51 | 0.2 |
| Other Long Term Assets Total | 13.53 | 16.62 | 14.34 |
| Note Receivable-Long Term | 7.65 | Not available | Not available |
| Total Current Assets | 957.04 | 1,005.95 | 705.64 |
| Capital Lease Obligations | 37.58 | 16.53 | 0.38 |
| Accumulated Depreciation Total | Not available | -120.37 | -103.51 |
| Accrued Expenses | Not available | 3 | 8.4 |
| Prepaid Expenses | Not available | 1.46 | 0.99 |
| Property/Plant/Equipment Total-Gross | Not available | 420.43 | 275.25 |
| Notes Payable/Short Term Debt | Not available | 0 | 0 |
Fundamentals
Valuation and ratios
Valuation
PEG Ratio2.78
Price to Sale Ratio11.72
Growth
Debt 5Yr CAGR %-3.96
Margins
Operating Margin 12m27.79
Operating Margin 5y Avg30.39
Net Profit Margin 12m26.52
Net Profit Margin 5y25.86
Yield
Dividend Yield %0.2
Risk and consensus
Source-qualified signals
Risk metrics
Overall RiskHigh risk
Board Risk56.6
Analyst consensus
ConsensusBuy
Consensus score2.00
Analyst opinions6
Strong Sell count0
Sell count1
Hold count1
Buy count1
Strong Buy count3
Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.Industry context
Peer comparison
Only peers present in the company profile payload are displayed.
| Company | Price | Market cap | P/E | Research |
|---|---|---|---|---|
| Sun Pharmaceutical Industries | INR 1,944 | 4.66 L | 38.4 | — |
| Divi's Laboratories | INR 8,291.55 | 2.20 L | 73.32 | — |
| Torrent Pharmaceuticals | INR 4,965 | 1.89 L | 72.73 | — |
| Cipla | INR 1,475 | 1.19 L | 27.57 | — |
| Zydus Lifesciences | INR 1,106.25 | 1.10 L | 21.19 | — |
Shareholding
Ownership
- Promoter
- 73.15%
- FII
- 0.63%
- MF
- 5.18%
- Other
- 21.04%
Company intelligence
Latest relevant news
Source, timestamp and external destination are shown. Provider relevance scores are not available.
Blue Jet Healthcare wins EcoVadis Silver Medal for sustainability - scanx.tradeMarket news · 20 Jul 2026, 3:15 pm
Blue Jet Healthcare wins EcoVadis Silver Medal for sustainability scanx.trade
AZB, Cyril Amarchand Mangaldas, Hogan Lovells act on Blue Jet Healthcare ₹800 crore QIP - Bar and BenchMarket news · 15 Jul 2026, 5:19 pm
AZB, Cyril Amarchand Mangaldas, Hogan Lovells act on Blue Jet Healthcare ₹800 crore QIP Bar and Bench
Enterprise value to EBITDA forward of Blue Jet Healthcare Limited – NSE:BLUEJET - TradingViewMarket news · 15 Jul 2026, 5:11 pm
Enterprise value to EBITDA forward of Blue Jet Healthcare Limited – NSE:BLUEJET TradingView
Cyril Amarchand Mangaldas advises Motilal Oswal Investment Advisor and ICICI Securities on QIP of Blue Jet Healthcare - SCC OnlineMarket news · 14 Jul 2026, 5:30 pm
Cyril Amarchand Mangaldas advises Motilal Oswal Investment Advisor and ICICI Securities on QIP of Blue Jet Healthcare SCC Online
Blue Jet Healthcare Raises ₹8,000 Million via Qualified Institutional Placement - The Globe and MailMarket news · 11 Jul 2026, 12:44 am
Blue Jet Healthcare Raises ₹8,000 Million via Qualified Institutional Placement The Globe and Mail
Blue Jet Healthcare raises ₹8000 million via QIP - scanx.tradeMarket news · 10 Jul 2026, 4:15 pm
Blue Jet Healthcare raises ₹8000 million via QIP scanx.trade
Corporate actions
Events
- board MeetingsQuarterly Results
- annual General MeetingEGM
- dividendRs.1.2000 per share(60%)Final Dividend
- board MeetingsAudited Results, Dividend & Fund Raising
- board MeetingsQuarterly Results
- board MeetingsQuarterly Results
- annual General MeetingAGM
- dividendRs.1.2000 per share(60%)Final Dividend
Rusaka Markets Community
Discussion and sentiment for Blue Jet Healthcare
Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.
Checking your Rusaka Markets account…
Company profile
Business information
What the company does
Blue Jet Healthcare Limited is an India-based company. The Company is engaged in the business of manufacturing artificial sweeteners, contrast media intermediates, pharma intermediate, active pharmaceutical ingredients (APIs) used in pharmaceutical and healthcare products. It serves as a business-to-business company. Its integrated contrast media intermediate portfolio includes advanced intermediates for both iodine-based contrast agents used in X-ray and CT imaging, as well as gadolinium-based contrast agents used in MRI diagnostics. It manufactures saccharin and supplies to the healthcare, pharma, animal feed, food and beverages industries globally. It offers end-to-end integrated solutions from process development to commercialization of NCEs, advance intermediates, APIs and building blocks. Its expertise in Amino Acid-based derivatives develops and manufactures them on a small scale and is in the process of building multi-modular production blocks for large-scale manufacturing.
Company facts
- Industry
- Biotechnology & Drugs
- Sector
- Biotechnology & Drugs
- NSE Code
- BLUEJET
- BSE Code
- 544009
Questions
Stock FAQ
What is the symbol and ISIN of Blue Jet Healthcare?
Blue Jet Healthcare has the symbol BLUEJET and ISIN - INE0KBH01020.
What is the current price of Blue Jet Healthcare?
Blue Jet Healthcare is currently trading at INR 568.20.
What are the year high and year low of Blue Jet Healthcare?
Blue Jet Healthcare has a year high of INR 834.95 and a year low of INR 325.00.
What is the market capitalization of Blue Jet Healthcare?
Blue Jet Healthcare has a market capitalization of INR 11,099.51 crore.
What is the P/E ratio of Blue Jet Healthcare?
Blue Jet Healthcare has a P/E ratio of 38.76.
What is the dividend yield of Blue Jet Healthcare?
Blue Jet Healthcare has a dividend yield of 0.20%.
How is the financial performance of Blue Jet Healthcare based on revenue, net income, and EPS?
Blue Jet Healthcare has revenue of INR 947.32 crore, net income of INR 247.82 crore, and EPS of INR 13.55.
What is the book value of Blue Jet Healthcare?
Blue Jet Healthcare has a book value of NA.
What is the debt-to-equity ratio of Blue Jet Healthcare?
Blue Jet Healthcare has a debt-to-equity ratio of NA.
What are the price-to-book and price-to-sales ratios of Blue Jet Healthcare?
Blue Jet Healthcare has a price-to-book ratio of NA and a price-to-sales ratio of 11.72.
Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.